DERIVATIVES OF TETRAHYDROISOQUINOLINE, PHARMACEUTICAL COMPOSITION CONTAINING THEREOF, METHOD FOR INHIBITION OF SYNAPTIC UPTAKE OF DOPAMINE AND TREATMENT METHOD Russian patent published in 2007 - IPC C07D217/04 C07D217/14 C07D217/16 C07D217/24 A61K31/472 A61P25/00 

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to novel tetrahydroisoquinolines that are useful in treatment of different neurological and psychic disorders, for example, ADHD. Invention describes a derivative of tetrahydroisoquinoline represented by the formula (IA-IF): wherein carbon atom designated as * is in R- or S-configuration; R¹ represents (C₁-C₆)-alkyl; R² represents hydrogen atom (H), (C₁-C₆)-alkyl; R³ represents H, -S(O)_nNR¹¹R¹², (C₁-C₆)-alkyl or if R represents (C₁-C₆)-alkyl then the indicated group is substituted optionally with 1-3 substitutes chosen independently from the following groups in each case: (C₁-C₆)-alkyl, -OR⁹ and -NR⁹R¹⁰ under condition that in compounds represented by the formula (IA) radical R³ represents (C₁-C₆)-alkyl that is substituted optionally with 1-3 substitutes chosen independently among the following groups in each case: (C₁-C₆)-alkyl, -OR⁹ and -NR⁹R¹⁰; R⁴ represents H, (C₁-C₆)-alkyl, and when R⁴ represents (C₁-C₆)-alkyl then indicated group is substituted optionally with 1-3 substitutes chosen independently from the following groups in each case: (C₁-C₃)-alkyl, halogen atom, -OR⁹ and -NR⁹R¹⁰ under condition that in compounds represented by the formula (ID) radical R⁴ represents (C₁-C₆)-alkyl that is optionally substituted, and wherein both R³ and R are not hydrogen atom; each R⁵, R⁶ and R⁷ in compounds represented by each formula (IA), (IB), (IC), (ID), (IE) and (IF) represents independently H, halogen atom, -OR¹¹, -NR¹¹C(O)R¹² and (C₁-C₆)-alkyl, and when each radical among R⁵, R⁶ and R⁷ represents (C₁-C₆)-alkyl then indicated group is substituted optionally with 1-3 substitutes chosen independently in each case from the following groups: (C₁-C₃)-alkyl, halogen atom under condition that in compounds represented by the formula (IE) at least one radical among R⁵ or R⁷ represents fluorine, chlorine atom or methyl group; R⁸ represents H or halogen atom under condition that in compounds represented by the formula (IF) radical R represents halogen atom; each R⁹ and R¹⁰ represents independently H, (C₁-C₄)-alkyl; R¹¹ represents H, (C₁-C₄)-alkyl, and when R¹¹ represents (C₁-C₄)-alkyl then indicated group is substituted optionally with 1-3 substitutes chosen independently in each case from the following groups: halogen atom, (C₁-C₄)-alkyl; R¹² represents H, (C₁-C₄)-alkyl; n = 2, and its pharmaceutically acceptable salt or solvate. Also, invention describes a pharmaceutical composition, a method for treatment of disorder caused or associated with deficiency in serotonin, noradrenaline or dopamine, a method for inhibition of synaptic uptake of noradrenaline, a method for inhibition of synaptic uptake of serotonin, a method for inhibition of synaptic uptake of dopamine and a set comprising, among them, a compound by cl. 1. Invention provides synthesis of novel compounds possessing the useful biological properties.

EFFECT: valuable medicinal properties of compounds and pharmaceutical composition, improved method of treatment and inhibition.

44 cl, 5 tbl, 94 ex